Literature DB >> 2475709

Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations.

W Danielsen1, H v der Leyen, W Meyer, J Neumann, W Schmitz, H Scholz, J Starbatty, B Stein, V Döring, P Kalmár.   

Abstract

We measured force of contraction and cAMP content in human isolated electrically driven right ventricular trabeculae carneae with and without the addition of isoprenaline (0.2 microM). Basal cAMP content was approximately 200% higher in preparations from nonfailing hearts than from hearts with end-stage myocardial failure. Isoprenaline was less effective in increasing force of contraction in failing (by approximately 100%) than in nonfailing cardiac preparations (by approximately 500%). With isoprenaline, cAMP content was approximately 50% lower in failing than in nonfailing preparations. We conclude that the reduced increase in force of contraction of failing human cardiac preparations with isoprenaline added may be causally related to an inadequately increased cAMP content.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475709     DOI: 10.1097/00005344-198907000-00026

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  23 in total

Review 1.  Transcriptional regulation by cAMP in the heart.

Authors:  F U Müller; J Neumann; W Schmitz
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

2.  Functional properties of the rat phosphatase 1alpha promoter.

Authors:  B Linck; P Boknik; J Knapp; K Kikuchi; H Lüss; F U Müller; K Nomoto; J Neumann; W Schmitz
Journal:  Mol Cell Biochem       Date:  2001-07       Impact factor: 3.396

3.  Distinct down-regulation of cardiac beta 1- and beta 2-adrenoceptors in different human heart diseases.

Authors:  M Steinfath; B Geertz; W Schmitz; H Scholz; A Haverich; I Breil; P Hanrath; C Reupcke; M Sigmund; H B Lo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

4.  Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts.

Authors:  S Bartel; B Stein; T Eschenhagen; U Mende; J Neumann; W Schmitz; E G Krause; P Karczewski; H Scholz
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

Review 5.  Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure.

Authors:  W Schmitz; P Boknik; B Linck; F U Müller
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

6.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

7.  Acceleration of contraction by beta-adrenoceptor stimulation is greater in ventricular myocytes from failing than non-failing human hearts.

Authors:  S E Harding; L A Brown; F del Monte; C H Davies; P O'Gara; G Vescovo; D G Wynne; P A Poole-Wilson
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

8.  Effect of epinine on tension of human renal arteries.

Authors:  R H Schwinger; C Schulz; K Brixius; M Böhm; J Müller-Ehmsen; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

9.  Incomplete reversal of beta-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors.

Authors:  D G Wynne; P A Poole-Wilson; S E Harding
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

Review 10.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.